Virtual Library

Start Your Search

Shuji Murakami



Author of

  • +

    EP1.01 - Advanced NSCLC (ID 150)

    • Event: WCLC 2019
    • Type: E-Poster Viewing in the Exhibit Hall
    • Track: Advanced NSCLC
    • Presentations: 1
    • Now Available
    • Moderators:
    • Coordinates: 9/08/2019, 08:00 - 18:00, Exhibit Hall
    • +

      EP1.01-72 - Treatment Outcome of 2nd Generation EGFR-TKI for Non-Small Cell Lung Cancer (Now Available) (ID 1988)

      08:00 - 18:00  |  Author(s): Shuji Murakami

      • Abstract
      • Slides

      Background

      Efficacy of EGFR-TKI has been demonstrated in 1st line treatment for EGFR mutation positive NSCLC. Afatinib, 2nd generation EGFR-TKI inhibits HER2 (ErbB2) or ErbB4 in addition to the EGFR (ErbB1), is expected more effective compared to the 1st generation EGFR-TKI. In this study, we investigated retrospectively on the treatment outcome of the cases that received 2nd generation EGFR-TKI treatment at our institution.

      Method

      The subjects were 70 patients treated with a 2nd generation EGFR-TKI afatinib for the period from May 2014 to April 2018. Age, gender, smoking history, performance status (ECOG), EGFR mutation type, starting dose, dose reduction during treatment period, objective response, presence of brain metastasis, EGFR-TKI treatment line and T790M mutation result were retrospectively analyzed the association with the time to treatment failure and survival.

      Result

      Among the 70 patients, male 28 cases and female 42 cases, and 42 never smoker included. Median age was 65 years old (43-88 years old). EGFR mutation type included exon 19 deletion 42 cases, exon 21 L858R 13 cases, uncommon mutation 13 cases and compound mutation 2 cases. 18 cases were administered with 40mg initial dose, 28 cases were 30mg and 24 cases were 20mg. 68 cases were good performance status (0 or 1), and 33 (47%) cases had brain metastasis. Dose reduction were performed in 43 (61%) cases, and partial response were observed in 34 (49%) cases. 36 (51%) cases were no pretreatment with EGFR-TKI (afatinib as first EGFR-TKI). Of the 70 cases, 33 (47%) cases were performed re-biopsy, and 15 cases of those were proved T790M acquired resistant mutation.

      Conclusion

      Good performance status, dose reduction, good objective response, no brain metastasis, early EGFR-TKI treatment line and T790M mutation positivity were significantly associated with prolongation of the time to treatment failure, but no significant characteristics were associated with prolongation of the survival.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.